European Medicines Agency (EMA) accepts license extension application for sodium thiosulfate infusion for cisplatin-induced hearing loss in children

The application is based on 2 phase III studies: the Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6 in which children (aged 1month to 18yrs) were treated with intensive cisplatin regimen for hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, and medulloblastoma


Biospace Inc.